^
    BIOMARKER:

    HER-2 positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2




    Show legend

    Include preclinical:
    HER2 Positive Breast Cancer
    Gastric Cancer
    Gastroesophageal Junction Adenocarcinoma
    Colorectal Cancer
    Solid Tumor
    Biliary Tract Cancer
    Gastroesophageal Cancer
    Non Small Cell Lung Cancer
    Salivary Gland Cancer
    Esophageal Adenocarcinoma
    Urothelial Cancer
    Bladder Cancer
    Esophageal Cancer
    Pancreatic Cancer
    Cholangiocarcinoma
    Endometrial Cancer
    Ovarian Cancer
    Endometrial Adenocarcinoma
    Lung Cancer
    Thymic Carcinoma
    Gastric Adenocarcinoma
    Esophageal Squamous Cell Carcinoma
    Colon Cancer
    Melanoma
    Small Cell Lung Cancer
    Gastrointestinal Cancer
    Cervical Cancer
    Gallbladder Cancer
    Gastrointestinal Stromal Tumor
    Estrogen Receptor Positive Breast Cancer
    HER2-targeted CAR-T immunotherapy
    Tyrosine kinase inhibitor
    PH-FECH
    PCbTP
    THP
    TCHP
    FOLFIRI
    TCH
    HER2 inhibitor
    AC-TH
    AC
    AC-THP
    TH
    CD19-targeted CAR-T immunotherapy
    HER2 inhibitor + Erythropoiesis stimulating agent
    VIP
    TCbHP
    TC
    ECP-THP
    EC-TH
    Nab-PHP + PldCHP
    PD-L1 inhibitor
    trastuzumab
    fam-trastuzumab deruxtecan-nxki
    trastuzumab + lapatinib
    trastuzumab + abemaciclib
    pyrotinib
    PRS-343
    trastuzumab-pkrb
    trastuzumab + pertuzumab
    ramucirumab
    KN046 + KN026
    ado-trastuzumab emtansine
    pyrotinib + dalpiciclib
    disitamab vedotin
    Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
    SHR-A1811
    JNJ-0683
    TX05 (trastuzumab biosimilar)
    trastuzumab-dttb
    trastuzumab + camrelizumab
    A166
    trastuzumab + tucatinib
    trastuzumab-strf
    pembrolizumab + trastuzumab
    Hervelous (trastuzumab biosimilar)
    tucatinib
    trastuzumab-dkst
    trastuzumab-anns
    CYNK-101
    trastuzumab-qyyp
    neratinib
    margetuximab-cmkb + MGD013
    paclitaxel
    poziotinib
    pembrolizumab + margetuximab-cmkb
    pembrolizumab
    trastuzumab + ramucirumab
    MRG002
    irinotecan
    rivoceranib
    camrelizumab + pyrotinib
    trastuzumab + tislelizumab
    PF-06804103
    nivolumab + trastuzumab
    lapatinib
    nivolumab + fam-trastuzumab deruxtecan-nxki
    trastuzumab + ramucirumab + ALX148
    MCLA-128
    pertuzumab/trastuzumab/hyaluronidase-zzxf
    trifluridine/tipiracil
    tislelizumab + ZW25
    MT-5111
    BI 1810631
    ZW49
    nivolumab
    trastuzumab + atezolizumab + pertuzumab
    pertuzumab + trastuzumab-dttb
    albumin-bound paclitaxel
    BAT8001
    trastuzumab + tremelimumab
    etoposide oral
    MK-2206
    ZW25
    bevacizumab + trastuzumab
    azacitidine
    ASLAN001
    D3L-001
    camrelizumab + inetetamab
    pembrolizumab + ado-trastuzumab emtansine
    trastuzumab + copanlisib
    tislelizumab + disitamab vedotin
    margetuximab-cmkb
    LZM-005
    ado-trastuzumab emtansine + tucatinib
    trastuzumab + LZM-005
    anlotinib
    olaparib + durvalumab
    paclitaxel + minnelide
    MEDI4276
    pyrotinib + inetetamab
    DZD1516
    GQ1001
    pertuzumab + trastuzumab-pkrb
    ZN-A-1041
    BNT323
    IAH0968
    MM-302
    Tyrosine kinase inhibitor + capecitabine
    U3-1402
    ADC2122
    DP303c
    inetetamab
    pertuzumab + trastuzumab-strf
    carboplatin + albumin-bound paclitaxel
    HERtiCAD (trastuzumab biosimilar)
    trastuzumab + atezolizumab
    carboplatin
    KN026
    HP + eribulin mesylate
    Hercease (trastuzumab biosimilar)
    trastuzumab + rivoceranib
    pertuzumab + ado-trastuzumab emtansine
    trastuzumab + S-222611
    pertuzumab
    IKS014
    TAA013
    trastuzumab + MM-302
    EG12014 (trastuzumab biosimilar)
    trastuzumab + ramucirumab + tucatinib
    afatinib
    pertuzumab + inetetamab
    CT-0508
    trastuzumab + ruxolitinib
    neratinib + ado-trastuzumab emtansine
    epirubicin
    bevacizumab
    palbociclib + ado-trastuzumab emtansine
    trastuzumab duocarmazine
    capecitabine
    ACE1702
    pyrotinib + letrozole
    ALT-P7
    disitamab vedotin + zimberelimab
    trastuzumab + pyrotinib
    trastuzumab + brusatol
    durvalumab
    CH7C4
    VRN101099
    TQB3616
    trastuzumab + BMS-202
    dasatinib + lapatinib
    olaparib + fam-trastuzumab deruxtecan-nxki + BAY 1895344
    acalabrutinib
    zanubrutinib
    ibrutinib
    VERU-111
    TH 1902
    trastuzumab-IFN-β mutein
    pertuzumab + D3L-001
    alpelisib + pyrotinib
    MYX2449
    MF-TTZ-MMAE
    BT2111
    tucatinib + disitamab vedotin
    AZD1390
    fam-trastuzumab deruxtecan-nxki + tucatinib
    HF-CAR-PMs
    trametinib + neratinib
    everolimus + neratinib
    palbociclib + neratinib
    SAR446309
    trastuzumab + GS-4721
    ZEN-3694
    lapatinib + APG-1252
    entinostat
    LB-100
    trastuzumab + CYNK-101
    trastuzumab
    AB-201
    doxorubicin hydrochloride + decitabine
    ruxolitinib
    ado-trastuzumab emtansine + talazoparib
    trastuzumab + talazoparib
    trastuzumab + ZN-c3
    ZN-c3
    tucatinib + PRT3645
    PD-L1 inhibitor + oxaliplatin
    PRT3645
    NXP900
    atezolizumab + ado-trastuzumab emtansine
    FGX15-147-based ADC
    itraconazole
    dasatinib + neratinib
    everolimus + ado-trastuzumab emtansine
    EDIT-202
    trastuzumab + everolimus